First Trust Direct Indexing’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-10,466
Closed -$1.62M 240
2024
Q3
$1.62M Buy
10,466
+2,073
+25% +$310K 0.09% 237
2024
Q2
$1.15M Buy
8,393
+1,902
+29% +$260K 0.07% 284
2024
Q1
$864K Sell
6,491
-741
-10% -$96.1K 0.06% 326
2023
Q4
$997K Buy
7,232
+685
+10% +$90.1K 0.09% 260
2023
Q3
$798K Sell
6,547
-78
-1% -$10.4K 0.09% 267
2023
Q2
$931K Sell
6,625
-163
-2% -$22.5K 0.1% 231
2023
Q1
$960K Buy
6,788
+55
+0.8% +$7.87K 0.11% 221
2022
Q4
$1.05M Sell
6,733
-57
-0.8% -$8.19K 0.14% 184
2022
Q3
$833K Buy
6,790
+309
+5% +$40.7K 0.12% 222
2022
Q2
$862K Buy
6,481
+484
+8% +$66K 0.12% 224
2022
Q1
$821K Buy
5,997
+523
+10% +$72.9K 0.1% 260
2021
Q4
$947K Sell
5,474
-2
-0% -$304 0.12% 199
2021
Q3
$796K Buy
5,476
+1,541
+39% +$225K 0.11% 227
2021
Q2
$519K Buy
3,935
+2,254
+134% +$295K 0.08% 314
2021
Q1
$216K Sell
1,681
-1,081
-39% -$133K 0.06% 361
2020
Q4
$329K Buy
+2,762
New +$337K 0.09% 276

Other funds holding DGX

First Trust Direct Indexing's DGX Position: Q4 2024 in Review

First Trust Direct Indexing sold out of Quest Diagnostics (DGX) in Q4 2024, closing a stake of 10,466 shares — an estimated $1.62M sold.

First Trust Direct Indexing first reported a position in DGX in Q4 2020 and held it in 16 quarters. The position peaked at $1.62M in Q3 2024. 897 funds tracked by Wall St. Rank hold DGX as of Q4 2024.

  • First Trust Direct Indexing reported no remaining Quest Diagnostics position as of Q4 2024 after selling out during the quarter.
  • First Trust Direct Indexing sold 10,466 Quest Diagnostics shares in Q4 2024, an estimated $1.62M.
  • First Trust Direct Indexing first reported a position in Quest Diagnostics in Q4 2020 and held it in 16 quarters.
  • First Trust Direct Indexing's Quest Diagnostics position peaked at $1.62M in Q3 2024.
  • 897 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2024.

Based on First Trust Direct Indexing's 13F filing for Q4 2024.